Journal article

Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis

PJ Meunier, C Roux, S Ortolani, M Diaz-Curiel, J Compston, P Marquis, C Cormier, G Isaia, J Badurski, JD Wark, J Collette, JY Reginster

OSTEOPOROSIS INTERNATIONAL | SPRINGER LONDON LTD | Published : 2009

Abstract

SUMMARY: Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33% over 4 years, confirming the role of strontium ranelate as an effective long-term treatment in osteoporosis. INTRODUCTION: Osteoporotic vertebral fractures are associated with increased mortality, morbidity, and loss of quality-of-life (QoL). Strontium ranelate (2 g/day) was shown to prevent bone loss, increase bone strength, and reduce vertebral and peripheral fractures. The preplanned aim of this study was to evaluate long-term efficacy and safety of strontium ranelate. METHODS:..

View full abstract